Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9


JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.

Vainchenker W, Leroy E, Gilles L, Marty C, Plo I, Constantinescu SN.

F1000Res. 2018 Jan 17;7:82. doi: 10.12688/f1000research.13167.1. eCollection 2018. Review.


The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer.

Bishop JL, Thaper D, Zoubeidi A.

Cancers (Basel). 2014 Apr 9;6(2):829-59. doi: 10.3390/cancers6020829.


Blockade of glioma proliferation through allosteric inhibition of JAK2.

He K, Qi Q, Chan CB, Xiao G, Liu X, Tucker-Burden C, Wang L, Mao H, Lu X, McDonald FE, Luo H, Fan QW, Weiss WA, Sun SY, Brat DJ, Ye K.

Sci Signal. 2013 Jul 9;6(283):ra55. doi: 10.1126/scisignal.2003900.


Update on JAK2 Inhibitors in Myeloproliferative Neoplasm.

Chan D, Koren-Michowitz M.

Ther Adv Hematol. 2011 Apr;2(2):61-71. doi: 10.1177/2040620711401646.


Inhibition of the signalling kinase JAK3 alleviates inflammation in monoarthritic rats.

Kim BH, Kim M, Yin CH, Jee JG, Sandoval C, Lee H, Bach EA, Hahm DH, Baeg GH.

Br J Pharmacol. 2011 Sep;164(1):106-18. doi: 10.1111/j.1476-5381.2011.01353.x.


The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo.

Kirabo A, Embury J, Kiss R, Polgár T, Gali M, Majumder A, Bisht KS, Cogle CR, Keseru GM, Sayeski PP.

J Biol Chem. 2011 Feb 11;286(6):4280-91. doi: 10.1074/jbc.M110.200774. Epub 2010 Dec 2.


The recent medicinal chemistry development of Jak2 tyrosine kinase small molecule inhibitors.

Baskin R, Majumder A, Sayeski PP.

Curr Med Chem. 2010;17(36):4551-8. Review.


NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3.

Kim BH, Jee JG, Yin CH, Sandoval C, Jayabose S, Kitamura D, Bach EA, Baeg GH.

Mol Cancer. 2010 Feb 11;9:36. doi: 10.1186/1476-4598-9-36.

Supplemental Content

Support Center